Matrix metalloproteinase-3 serum levels in schizophrenic patients.
Saved in:
| Title: | Matrix metalloproteinase-3 serum levels in schizophrenic patients. |
|---|---|
| Authors: | Ordak, Michal, Libman-Sokolowska, Malgorzata, Nasierowski, Tadeusz, Badyra, Bogna, Kaczmarek, Leszek, Muszynska, Elzbieta, Bujalska-Zadrozny, Magdalena |
| Source: | International Journal of Psychiatry in Clinical Practice. Mar2023, Vol. 27 Issue 1, p1-7. 7p. |
| Subjects: | Drug therapy for schizophrenia, Matrix metalloproteinases, Sex distribution, Enzyme-linked immunosorbent assay, Questionnaires, Descriptive statistics, Antipsychotic agents |
| Abstract: | It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia. Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale. The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02). MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients. MMP3 could be used as a potential biomarker for schizophrenia. The level of MMP-3 decreased due to the applied antipsychotic treatment. The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease. [ABSTRACT FROM AUTHOR] |
| Copyright of International Journal of Psychiatry in Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia. Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale. The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02). MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients. MMP3 could be used as a potential biomarker for schizophrenia. The level of MMP-3 decreased due to the applied antipsychotic treatment. The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13651501 |
| DOI: | 10.1080/13651501.2022.2057332 |
